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Galectins, a family of evolutionarily-
conserved glycan-binding proteins, can 
influence tumor progression by mediating 
communication among tumor, stromal, 
endothelial and immune cells. These lec-
tins are defined by a consensus sequence 
of approximately 130 amino acids within 
the carbohydrate-recognition domain 
(CRD), which mediates their specific 
interaction with N-acetyllactosamine 
[Galβ(1–4)-GlcNAc]-enriched glycocon-
jugates.1 Within the intracellular com-
partment, galectins can modulate a variety 
of signaling processes.1 However, these 
endogenous lectins can also be secreted 
in the extracellular milieu through a non-
classical pathway, where they cross-link 
specific glycoconjugates and modulate a 
variety of cellular processes including pro-
liferation, differentiation and apoptosis.1 
A number of studies in preclinical models 
and cancer patients have documented a 
significant association between the expres-
sion of galectins and the aggressiveness of 
multiple tumor types. In most settings, 
galectin expression is associated with 
poor clinical outcome.1 Of note, whereas 
15 galectins have been identified so far 
in a diversity of tissues and species, most 
studies have focused on galectin-1 and 
galectin-3.1
We and others have identified a critical 
role for galectin-1 in the evasion of tumor 
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cells from immune responses in differ-
ent types of cancer, including melanoma, 
Hodgkin’s lymphoma, lung carcinoma 
and neuroblastoma.1–5 The analysis of 
the mechanisms underlying these effects 
revealed the ability of galectin-1 to modu-
late T-cell survival, dendritic-cell immuno-
genicity and regulatory T-cell function.1–5 
In addition, galectin-1 is strongly upregu-
lated by hypoxia and has been shown to 
promote angiogenesis in different tumor 
types, including melanoma and Kaposi’s 
sarcoma.6–8 However, despite considerable 
progress in the understanding of the roles 
of individual galectins in tumor biology, 
an integrated view of the galectin network 
in the tumor microenvironment, includ-
ing their regulation and coordinated func-
tion is still lacking. In an attempt to fill 
this gap, we conducted a study to delin-
eate the ‘galectin signature’ of the human 
prostate cancer (PCa) microenvironment 
with the overarching goal of selecting 
novel molecular targets for prognostic and 
therapeutic purposes.9
The analysis of the galectin profile in 
prostatectomies from a cohort of therapy-
naïve patients demonstrated that galec-
tin-1 is the most abundantly expressed 
galectin in this setting and is the only 
member of the family that is substan-
tially upregulated during PCa progres-
sion. A similar profile was observed in 
representative PCa cell lines, at both the 
mRNA and protein levels. All other galec-
tin family members are expressed at com-
paratively lower levels. While galectin-3, 
-4, -9 and -12 are downregulated in the 
course of the disease, the expression of 
galectin-8 does remain unaltered dur-
ing disease progression. The selective 
upregulation of galectin-1 prompted us 
to investigate the function of this lec-
tin in the PCa microenvironment. As 
galectin-1-N-glycan interactions can link 
tumor hypoxia to angiogenesis in Kaposi’s 
sarcoma,8 we examined whether this lec-
tin plays any role in PCa angiogenesis. In 
tissue arrays from PCa patients, elevated 
expression levels of galectin-1 correlated 
with increased number of blood vessels. 
This positive correlation was even more 
pronounced during advanced stages of the 
disease. However, no significant correla-
tion was found in human breast cancer 
tissue arrays, suggesting a tissue-specific 
pro-angiogenic effect of this lectin.9
Given the promising therapeutic value 
of anti-angiogenic regimens for advanced 
castration-resistant PCa,10 we examined 
the effects of targeting galectin-1 during 
PCa angiogenesis. In vitro, the blockade 
of galectin-1 using a newly-developed 
neutralizing monoclonal antibody pre-
vented the morphogenesis of endothe-
lial cells as induced by human PCa cell 
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cancers are refractory to conventional 
chemotherapeutic, anti-angiogenic and 
immunotherapeutic agents, our results 
suggest an alternative strategy to sup-
press tumor growth and prevent tumor 
metastasis. Importantly, the blockade of 
galectin-1 may serve not only to prevent 
tumor angiogenesis, but also to stimulate 
T cell-mediated immunity and abrogate 
tumor-cell invasiveness and migration, as 
previously demonstrated in other tumor 
types2 (Fig. 1).
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suggesting a pivotal role for this lectin in 
tumor neovascularization.
Collectively, our findings identify a 
dynamically regulated ‘galectin signa-
ture’, which accompanies the evolution 
of PCa, highlighting a major role for 
galectin-1 as a target for anti-angiogenic 
therapy in castration-resistant advanced 
stages of the disease. Similar to recent 
findings in melanoma6,7 and Kaposi’s 
sarcoma,8 we found that galectin-1 is a 
pivotal stimulator of PCa neovasculariza-
tion independently of other angiogenesis-
related molecules,9 and demonstrated 
that tumor cells are the primary source 
of this pro-angiogenic lectin. As many 
lines. Furthermore, the inhibition of 
galectin-1 expression in vivo by means of 
lentiviral-transduced short-hairpin RNAs 
(shRNAs) or upon injection of the galec-
tin-1 neutralizing antibody prevented 
angiogenesis as induced by Matrigel-
embedded PCa cells. These results dem-
onstrate that silencing galectin-1 in PCa 
cells is sufficient to prevent angiogen-
esis, as tumor cells transduced with a 
galectin-1-specific shRNA almost com-
pletely failed to form blood vessels even 
in the presence of the host-derived lectin. 
Interestingly, the pro-angiogenic effects of 
galectin-1 were independent of the expres-
sion of other angiogenesis-related factors, 
Figure 1. A unique ‘galectin signature’ delineates human prostate cancer progression. the analysis of the galectin profile in a cohort of therapy-naïve 
prostatectomies demonstrated that galectin (Gal)-1 is the most abundant galectin in this setting and the only member of the family that is substan-
tially upregulated during prostate cancer (PCa) progression. while Gal-3, -4, -9 and -12 are downregulated in the course of the disease, Gal-8 expres-
sion levels remain virtually unaltered. targeting Gal-1 suppresses PCa angiogenesis, suggesting a novel molecular target for the therapy of castration-
resistant advanced stages of the disease. t1, t2, t3 and t4 indicate different stages of PCa evolution.
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